FDA recalls contaminated OTC pain reliever nationwide plus APAP/aspirin/NSAID safety alerts + AEMS AI tracker
Key Questions
What is the FDA recall mentioned in this highlight?
The FDA issued a nationwide recall in March 2026 for a contaminated over-the-counter (OTC) pain reliever. This action addresses safety concerns related to APAP (acetaminophen) and other analgesics.
What safety alerts are associated with APAP, aspirin, and NSAIDs?
AEMS tracks risks with APAP, Benadryl, decongestants, and NSAIDs, including interactions with multis, captopril, telmisartan+NSAID, ibuprofen, and Qivigy that affect kidneys, blood pressure, alcohol use, thalidomide, and enalapril. Aspirin and NSAIDs increase bleeding and cardiovascular risks, contributing to 178,000 emergency room visits from polypharmacy.
What new drug interaction flags have been identified?
New flags include telmisartan + naproxen and ibuprofen + Qivigy, highlighting potential kidney and blood pressure issues. These are part of broader monitoring for OTC pain relievers and common medications.
How does alcohol interact with these pain relievers?
Alcohol, even at lower intake levels, varies by type (e.g., beer, cider) and can exacerbate risks with APAP, NSAIDs, and other analgesics, increasing liver and other organ damage potential.
What interactions are noted with specific drugs like Micardis or Qivigy?
Micardis (telmisartan) with naproxen shows 53 potential interactions, while ibuprofen with Qivigy has 46, focusing on cardiovascular, kidney, and bleeding risks.
FDA Mar 2026 recall; AEMS tracks APAP/Benadryl/decongestants/NSAIDs; multis + captopril/telmisartan+NSAID/ibuprofen+Qivigy kidney/BP/alcohol/thalidomide/enalapril; aspirin/NSAIDs bleed/CV; 178k ER/polypharmacy. New telmisartan+naproxen, Qivigy flags.